Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

Market Cap	8.11B -26.2%
Revenue (ttm)	1.40B -6.8%
Net Income	117.11M +60.6%
EPS	0.25 +51.6%
Shares Out	455.90M
PE Ratio	71.12
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,536,000
Open	17.40
Previous Close	17.56
Day's Range	16.79 - 17.83
52-Week Range	16.24 - 32.99
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:600645

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells and dental stem cells. The company also provides prenatal genetic testing for pregnancy, children and adults, disease inheritance, and disease susceptibility; and in ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,935
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600645

Financial Performance

In 2025, SHA:600645's revenue was 1.45 billion, a decrease of -8.23% compared to the previous year's 1.59 billion. Earnings were 113.83 million, an increase of 13.43%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error